Literature DB >> 34338919

Metastatic clear cell renal cell carcinoma: computed tomography texture analysis as predictive biomarkers of survival in patients treated with nivolumab.

Zine-Eddine Khene1,2,3, Romain Kokorian4, Romain Mathieu5, Anis Gasmi5, Rioux-Leclercq Nathalie6, Kammerer-Jacquet Solène-Florence6, Shahrokh Shariat7, Renaud de Crevoisier4,8, Brigitte Laguerre4, Karim Bensalah5,8.   

Abstract

INTRODUCTION: To evaluate the value of image-based texture analysis for predicting progression-free survival (PFS) and overall survival (OS) in patients with metastatic clear cell renal carcinoma (cCCR) treated with nivolumab.
METHODS: This retrospective study included 48 patients with metastatic cCCR treated with nivolumab. Nivolumab was used as a second- or third-line monotherapy. Texture analysis of metastatic lesions was performed on CT scanners obtained within 1 month before treatment. Texture features related to the gray-level histogram, gray-level co-occurrence, run-length matrix features, autoregressive model features, and Haar wavelet feature were extracted. Lasso penalized Cox regression analyses were performed to identify independent predictors of PFS and OS.
RESULTS: Median PFS and OS were 5.7 and 13.8 months. 39 patients experienced progression and 27 died. The Lasso penalized Cox regression analysis identified three texture parameters as potential predictors of PFS: skewness, S.2.2. Correlat and S.1.1. SumVarnc. Multivariate Cox regression analysis confirmed skewness (HR (95% CI) 1.49 [1.21-1.85], p < 0.001) as an independent predictor of PFS. Regarding OS, the Lasso penalized Cox regression analysis identified three texture parameters as potential predictors of OS: S20SumVarnc, S22Contrast and S22Entropy. Multivariate Cox regression analysis confirmed S22Entropy (HR (95% CI) 1.68 (1.31-2.14), p < 0.001) as an independent predictor of OS.
CONCLUSIONS: Results from this preliminary study suggest that CT texture analysis might be a promising quantitative imaging tool that predicts oncological outcomes after starting nivolumab treatment.
© 2021. Japan Society of Clinical Oncology.

Entities:  

Keywords:  Haralick; Immunotherapy; Kidney cancer; Renal cell carcinoma; Texture analysis

Year:  2021        PMID: 34338919     DOI: 10.1007/s10147-021-02003-w

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  4 in total

1.  What Do International Guidelines Say About First-line Therapy for Clear-cell Metastatic Renal Cell Carcinoma?

Authors:  Myuran Thana; Lori Anne Wood
Journal:  Eur Urol Focus       Date:  2019-10-17

2.  CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.

Authors:  Masoom A Haider; Alireza Vosough; Farzad Khalvati; Alexander Kiss; Balaji Ganeshan; Georg A Bjarnason
Journal:  Cancer Imaging       Date:  2017-01-23       Impact factor: 3.909

3.  Gender-specific discrepancy in subjective global assessment for mortality in hemodialysis patients.

Authors:  Ye Eun Ko; Taeyoung Yun; Hye Ah Lee; Seung-Jung Kim; Duk-Hee Kang; Kyu Bok Choi; Yon Su Kim; Yong-Lim Kim; Hyung Jung Oh; Dong-Ryeol Ryu
Journal:  Sci Rep       Date:  2018-12-14       Impact factor: 4.379

4.  Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.

Authors:  S Trebeschi; S G Drago; N J Birkbak; I Kurilova; A M Cǎlin; A Delli Pizzi; F Lalezari; D M J Lambregts; M W Rohaan; C Parmar; E A Rozeman; K J Hartemink; C Swanton; J B A G Haanen; C U Blank; E F Smit; R G H Beets-Tan; H J W L Aerts
Journal:  Ann Oncol       Date:  2019-06-01       Impact factor: 32.976

  4 in total
  1 in total

Review 1.  Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy.

Authors:  Laurent Dercle; Jeremy McGale; Shawn Sun; Aurelien Marabelle; Randy Yeh; Eric Deutsch; Fatima-Zohra Mokrane; Michael Farwell; Samy Ammari; Heiko Schoder; Binsheng Zhao; Lawrence H Schwartz
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.